Recent Activity

Loading...

IMVT

Immunovant Inc · NASDAQ

Performance

+3.37%

1W

+0.99%

1M

-17.32%

3M

-8.96%

6M

-27.13%

YTD

+45.36%

1Y

Profile

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

Investment Analysis Report: IMVT

Overview

In this investment analysis report, we will analyze the stock of IMVT, a company in the Health Technology sector, specifically in the Biotechnology industry. We will delve into the financial health, earnings and revenue growth, profitability, operating margin, operating cash flow analysis, capital expend...

See more ...

Technical Analysis of IMVT 2024-05-10

Overview:

In analyzing the technical indicators for IMVT over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive assessment of the stock's potential price movement. By examining these key factors, we aim to offer valuable insights and predictions for the next few days.

Trend Anal...

See more ...

Recent News & Updates